---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007259"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:33:44.908640+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ArriVent Q1 cash $205.5M, net loss $64.4M; Phase 3 enrollment completed for firmonertinib

## Summary
- Cash $205.5M as of March 31, 2025; net loss $64.4M (vs $17.4M YoY) due to $40M upfront payment to Lepu for ARR-217.
- Completed enrollment in global pivotal Phase 3 FURVENT study for firmonertinib in first-line NSCLC EGFR exon20 insertion mutations.
- Plans to provide update on firmonertinib in EGFR PACC mutant NSCLC in Q2 2025; topline Phase 3 data expected in 2025.
- First IND for ARR-217 (CDH17 ADC) submitted in China; initial focus on colorectal, pancreatic, and other GI cancers.
- Appointed Merdad Parsey, former Gilead CMO, to Board of Directors in April 2025.

## SEC filing metadata
- accession: 0001558370-25-007259
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/0001558370-25-007259-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000155837025007259/avbp-20250512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007259
- JSON: https://secwatch.observer/filing/0001558370-25-007259.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007259.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.